Matthew Scott  Harris net worth and biography

Matthew Harris Biography and Net Worth

Insider of Altimmune
Dr. Harris is a seasoned medical professional with extensive experience in hepatology and gastroenterology and broad expertise in managing clinical trials from early stage development through successful Phase 3 trials. He has led multidisciplinary forums on drug development and clinical trial design at national and international scientific meetings, and fostered collaborations between professional medical societies and the FDA. Previously, he was co-founder and Chief Medical Officer of Lyric Pharmaceuticals, helping raise a $21 million Series A round in 2014. He has also served as Chief Medical Officer of Avaxia Biologics, interim Chief Medical Officer of Tranzyme Pharma, and Chief Medical Officer of Ocera Therapeutics. Dr. Harris was also Chief Medical Officer and Vice President of Clinical Development at Napo Pharmaceuticals where he authored the pivotal clinical study that led to the approval of crofelemer (Mytesi®), the first Phase 2/3 adaptive trial design resulting in a drug approval. Earlier in his career he held senior roles in global clinical development and medical affairs at Otsuka Pharmaceuticals and Abbott. He sits on the faculty of Georgetown University School of Medicine as an Adjunct Professor, where he directs a course on drug development under a grant from the NIH. Dr. Harris has been a consultant on third-world drug development for the Bill and Melinda Gates Foundation and a speaker at national and international forums on drug development. Dr. Harris has an M.D. from Harvard Medical School and an MS in Administrative Medicine and Population Health from the University of Wisconsin Medical School. His post-graduate training includes residencies at John Hopkins Hospital and the University of Pennsylvania, and a Gastroenterology and Hepatology Fellowship at the Yale University School of Medicine.

What is Matthew Scott Harris' net worth?

The estimated net worth of Matthew Scott Harris is at least $339,105.98 as of March 23rd, 2023. Dr. Harris owns 33,311 shares of Altimmune stock worth more than $339,106 as of March 29th. This net worth estimate does not reflect any other investments that Dr. Harris may own. Additionally, Dr. Harris receives an annual salary of $643,040.00 as Insider at Altimmune. Learn More about Matthew Scott Harris' net worth.

How old is Matthew Scott Harris?

Dr. Harris is currently 71 years old. There are 4 older executives and no younger executives at Altimmune. Learn More on Matthew Scott Harris' age.

What is Matthew Scott Harris' salary?

As the Insider of Altimmune, Inc., Dr. Harris earns $643,040.00 per year. The highest earning executive at Altimmune is Dr. Vipin K. Garg Ph.D., President, CEO & Director, who commands a salary of $916,160.00 per year. Learn More on Matthew Scott Harris' salary.

How do I contact Matthew Scott Harris?

The corporate mailing address for Dr. Harris and other Altimmune executives is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. Altimmune can also be reached via phone at (240) 654-1450 and via email at [email protected]. Learn More on Matthew Scott Harris' contact information.

Has Matthew Scott Harris been buying or selling shares of Altimmune?

Matthew Scott Harris has not been actively trading shares of Altimmune during the last ninety days. Most recently, on Thursday, March 23rd, Matthew Scott Harris bought 10,000 shares of Altimmune stock. The stock was acquired at an average cost of $4.22 per share, with a total value of $42,200.00. Following the completion of the transaction, the insider now directly owns 33,311 shares of the company's stock, valued at $140,572.42. Learn More on Matthew Scott Harris' trading history.

Are insiders buying or selling shares of Altimmune?

During the last twelve months, Altimmune insiders bought shares 1 times. They purchased a total of 300 shares worth more than $864.00. The most recent insider tranaction occured on August, 15th when Director David Drutz bought 300 shares worth more than $864.00. Insiders at Altimmune own 4.1% of the company. Learn More about insider trades at Altimmune.

Information on this page was last updated on 8/15/2023.

Matthew Scott Harris Insider Trading History at Altimmune

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/23/2023Buy10,000$4.22$42,200.0033,311View SEC Filing Icon  
2/28/2022Sell30,000$7.52$225,600.00View SEC Filing Icon  
See Full Table

Matthew Scott Harris Buying and Selling Activity at Altimmune

This chart shows Matthew Scott Harris's buying and selling at Altimmune by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Altimmune Company Overview

Altimmune logo
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $10.18
Low: $8.84
High: $10.50

50 Day Range

MA: $9.90
Low: $8.22
High: $13.81

2 Week Range

Now: $10.18
Low: $2.09
High: $14.84

Volume

8,490,847 shs

Average Volume

6,066,153 shs

Market Capitalization

$546.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08